OOIR: Observatory of International Research

Papers

(The H4-Index of JCO Precision Oncology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer	78
Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion	75
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care	72
Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer	71
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics	70
Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy	65
Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma	64
Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome	64
Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B	63
Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block	63
Association of RNF43 Genetic Alterations With BRAF^V600E and MSI^high in Colorectal Cancer	62
Identification of a Suitable Subgroup for Radiation Dose Escalation in Definitive Concurrent Chemoradiation Therapy for Nonmetastatic Esophageal Squamous Cell Carcinoma	59
CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD–1 Alone	55
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy	51
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine	51
Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Explora	48
Incidental Diffuse Midline Glioma, H3 K27-Altered of the Pons Without Significant Coalterations	48
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types	46
Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study	46
Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers	45
Identification and Validation of Gastric Adenocarcinoma Prognosis Features Based on Neutrophil-Related Genes	45
Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer	44
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas	44
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab	44
Prognostic Role of MTAP Loss in Cholangiocarcinoma	43

Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?	43
Parent Quality of Life After Disclosure of Pediatric Oncology Germline Sequencing Results	43
Role of Novel Bispecific Antibodies and Immunotherapy in Non–Small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations	42
Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms	42
Acknowledgment of Reviewers, 2025	41
Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR -Mutant Lung Cancer	40
Identification of Targetable EGFR Mutations in Ovarian Cancer	40
Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma	38
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review	38
Reply to: Beyond the Score: Integrating Hypoxia Signatures Into Risk-Adapted Stereotactic Body Radiation Therapy for Early-Stage Non–Small Cell Lung Cancer	38
Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma	37
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies	36